U.S. Markets close in 30 mins

Lawsuits Filed Against NNOX, MESO and FAF - Jakubowitz Law Pursues Shareholders Claims

·3 min read

NEW YORK, NY / ACCESSWIRE / November 3, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Nano-X Imaging Ltd. (NASDAQ:NNOX)

CONTACT JAKUBOWITZ ABOUT NNOX:
https://claimyourloss.com/securities/nano-x-imaging-ltd-loss-submission-form/?id=10678&from=1

Class Period: August 21, 2020 - September 15, 2020

Lead Plaintiff Deadline: November 16, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Mesoblast Limited (NASDAQ:MESO)

CONTACT JAKUBOWITZ ABOUT MESO:
https://claimyourloss.com/securities/mesoblast-limited-loss-submission-form/?id=10678&from=1

Class Period: April 16, 2019 - October 1, 2020

Lead Plaintiff Deadline: December 7, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

First American Financial Corp. (NYSE:FAF)

CONTACT JAKUBOWITZ ABOUT FAF:
https://claimyourloss.com/securities/first-american-financial-corp-loss-submission-form/?id=10678&from=1

Class Period: February 17, 2017 - October 22, 2020

Lead Plaintiff Deadline: December 24, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers' sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/614286/Lawsuits-Filed-Against-NNOX-MESO-and-FAF--Jakubowitz-Law-Pursues-Shareholders-Claims